临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Ombitasvir (ABT-267)
中文名称:翁比他韦
CAS号:1258226-87-7
分子式: C50H67N7O8 分子量: 894.11
产品形式: free base
研发状态: Completed
研发用途: Hepatitis C Virus
研究机构: AbbVie
研发日期: January 14 2016
研发阶段: --
Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Amikacin hydrate
中文名称:阿米卡星水合物
CAS号:1257517-67-1
分子式: C22H43N5O13.xH2O 分子量: 585.6+x18
产品形式: Hydrate
研发状态: Recruiting
研发用途: Tuberculosis Multidrug-Resistant
研究机构: Rwanda Biomedical Centre; Institute of Tropical Medicine; World Health Organization
研发日期: March 1 2023
研发阶段: Phase 2
Amikacin(BAY416651 hydrate) is an aminoglycoside antibiotic used to treat different types of bacterial infections.
BMS-986020
中文名称:-[3-甲基-4-[[[((R)-1-苯基乙基)氧基]羰基]氨基]异恶唑-5-基]联苯-4-基]环丙烷羧酸
CAS号:1257213-50-5
分子式: C29H26N2O5 分子量: 482.53
产品形式: Free Base
研发状态: Completed
研发用途: Immunosuppression For Disease
研究机构: Bristol-Myers Squibb
研发日期: Mar-14
研发阶段: Phase 1
BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
Venetoclax (ABT-199)
中文名称:维纳妥拉(ABT-199)
CAS号:1257044-40-8
分子式: C45H50ClN7O7S 分子量: 868.44
产品形式: free base
研发状态: Not yet recruiting
研发用途: Leukemia Myeloid Acute
研究机构: Delta-Fly Pharma Inc.
研发日期: May 31 2024
研发阶段: Phase 1 : Phase 2
Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
Alectinib (CH5424802)
中文名称:艾乐替尼
CAS号:1256580-46-7
分子式: C30H34N4O2 分子量: 482.62
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Non-small Cell Lung Cancer
研究机构: Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair; Medicine Invention Design Inc
研发日期: March 8 2024
研发阶段: Phase 2 : Phase 3
Alectinib (CH5424802, AF-802, RG-7853) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.
Emvododstat (PTC299)
CAS号:1256565-36-2
分子式: C25H20Cl2N2O3 分子量: 467.34
产品形式: Free base
研发状态: Terminated
研发用途: Leukemia Myeloid Acute; AML
研究机构: PTC Therapeutics
研发日期: October 29 2018
研发阶段: Phase 1
Emvododstat(PTC299), a post-transcriptional inhibitor of pathogenic VEGF and dihydroorotate dehydrogenase(DHODH), inhibits VEGFA mRNA translation and abnormal cell proliferation. In HeLa cells PTC299 inhibits hypoxia-induced VEGFA protein production with an EC50 of 1.64 nM.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
